INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE AND BORA PHARMACEUTICALS ANNOUNCED A STRATEGIC ALLIANCE FOR AI-DRIVEN DRUG DISCOVERY AND DEVELOPMENT

This announcement is made by InSilico Medicine Cayman TopCo (the "**Company**", together with its subsidiaries, the "**Group**" or "**Insilico Medicine**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that, Insilico Medicine has announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd. ("**Bora**"; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing (the "**Alliance**"). The Alliance lays the foundation for a broad, multi-target collaboration framework, subject to the parties' further discussion and execution of definitive agreements. If fully implemented, the potential value of the proposed collaboration under the Alliance could exceed USD2.5 billion.

The proposed collaboration under the Alliance will be governed by definitive agreements to be discussed and executed by Insilico Medicine and Bora. It is designed to combine Insilico Medicine's proprietary Pharma.AI platform, spanning target discovery, generative chemistry, and molecule optimization, with Bora's global development, manufacturing, quality, and commercialization capabilities. By linking AI-enabled discovery with automation-driven development, manufacturing, and quality execution, Insilico Medicine and Bora aim to pioneer a next-generation drug innovation model that connects novel molecule design with the capabilities required to develop, manufacture, and deliver medicines to patients with unmet medical needs.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, July 15, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.